Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer

The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tinglin, Li, Wenhui, Huang, Tao, Zhou, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055616/
https://www.ncbi.nlm.nih.gov/pubmed/36983708
http://dx.doi.org/10.3390/jpm13030526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055616/
https://www.ncbi.nlm.nih.gov/pubmed/36983708
http://dx.doi.org/10.3390/jpm13030526

Ejemplares similares